(Q80199403)
English
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll
scientific article published on 31 August 2006
Statements
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) (English)
Roswitha Forstpointner
Michael Unterhalt
Martin Dreyling
Hans-Peter Böck
Roland Repp
Hannes Wandt
Christiane Pott
John F Seymour
Bernd Metzner
Annette Hänel
Tanja Lehmann
Frank Hartmann
Wolfgang Hiddemann
German Low Grade Lymphoma Study Group (GLSG)
31 August 2006